GE HealthCare’s PET Imaging Agent Gains Alzheimer’s Label Expansion - Pharmaceutical Technology

FDA Approves Multiple New Indications for the Brain PET Imaging Agent Vizamyl

Expanded indications for the flutemetamol F18 injection include amyloid quantification and monitoring of anti-amyloid treatments.

GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.The post GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion appeared first on Medical Device Network.

GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion - Pharmaceutical Technology

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.